Table 2.
Patient outcomes
| ND-AML | RR-AML | P-value | ||
|---|---|---|---|---|
| VA (n = 8) | VA (n = 10) | HVA (n = 14) | ||
| Response, No (%) | ||||
| CR | 2(25) | 0 | 7 (50) | |
| CRi | 0 | 1 (10) | 2 (14.3) | |
| PR | 1 (12.5) | 1 (10) | 2 (14.3) | |
| No response | 5 (62.5) | 8 (80) | 3 (21.4) | |
| CR/CRi, No (%) | 2 (25) | 1 (10) | 9 (64.3) | |
| MRD-, No (%) | 2 (25) | 0 | 6 (42.9) | |
| Relapse, No (%) | 2 (100) | 0 | 1 (11.1) | |
| Mutation class, No (%) | ||||
| Methylation-related | 0 | 0 | 5 (55.5) | |
| Active signaling | 2 (50) | 0 | 3 (42.8) | |
| Chromatin modifiers | 1 (50) | 1 (25) | 2 (50) | |
| Tumor suppressor | 0 | 0 | 0 | |
AML acute myeloid leukemia, CR complete remission, CRi CR with incomplete hematological recovery, MRD minimal residual disease, PR partial remission, NR non-remission